Cystic Fibrosis Foundation distributed the following clinical trial update in April. Click the trial title to get more details.
April 1, 2019
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.
Age: 1 Years to 2 Years
Mutation: Two Copies F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 11
Length of Participation: 38 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03601637